Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
about
Insulin in central nervous system: more than just a peripheral hormoneNitric oxide and peroxynitrite in health and diseaseRole of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategiesNutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetesMitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatmentNew therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes.PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathyPARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function.Protective Pleiotropic Effect of Flavonoids on NAD⁺ Levels in Endothelial Cells Exposed to High Glucose.The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentinRole of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathyOxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondSulfasalazine blocks the development of tactile allodynia in diabetic rats.Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency.Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.Mouse models of diabetic neuropathy.Animal models and biomarkers of neuropathy in diabetic rodents.Accelerated aging during chronic oxidative stress: a role for PARP-1.New treatments for denervating diseases.PARP inhibitors attenuate chemotherapy-induced painful neuropathy.Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.
P2860
Q21296648-6A483194-CDB9-4022-BDDF-1485D6AF3820Q24645400-EC160FC6-53E3-4A39-862D-4E777F76E77DQ24656109-58328F8D-9D16-4961-9ED6-6208821BC28AQ28385506-A2999DC9-9758-4691-84AC-661082FA13EEQ33750650-AAF3DD14-2394-48F9-B551-8E1CECDF4D27Q33874485-8EE0D453-43C9-40B4-A8EF-464B75CED640Q34603026-1C278E21-5AA8-4D89-BDEE-30ABF01F8DE0Q34670090-0FADC4F9-321B-4EA9-B9D3-FE71E1505C90Q34851871-79FE1816-7A23-41EE-950D-9E98489ACFDFQ35769224-3A5B9855-FE75-4499-A580-B6B2C45400CBQ36165860-F0869CF4-9AF7-4829-8CC0-10DAF84A2001Q36203460-78354A99-7734-4133-9CEC-810D55E5C9B8Q36342643-27C3D01E-A527-4F86-8F1B-FE1E061F14ADQ36426843-53CEE5DD-5B57-4D5C-BA08-7BFF167696C2Q36431822-3E5F21AA-FE9B-4927-B4A0-D75A639E4621Q36431827-D7375AE4-B7D1-47BD-BC52-026F7BFD0BF6Q36853236-808556FD-2165-4E62-BFD2-72949BA943DAQ36906408-D97484D7-092A-408A-AE2D-22FDB527305DQ37230827-C00261D8-1AD3-4DF7-807A-CB48E46F1D58Q37373674-E6E44182-AA4A-40E2-BFA7-6E99AA21FCBFQ37373683-B23AE697-3C27-432E-B867-F32CD2D6913CQ37605348-B93D646D-CC59-4D1F-BB8B-E97585D21C77Q37655239-9742B98B-0C37-4A40-A87A-B79338FCC9DFQ41810562-005161F8-B367-460B-A6F1-C33E94BB00EFQ42127895-6D358368-2906-4F93-8707-9C9C9DE3E7B9Q46439343-F7024A9B-12B6-45EA-AF5F-70C5291E56D9Q46970236-7B14E72D-41C7-49D8-94D2-322D2463EF29Q46970415-4C6E9549-F656-40B5-A4DB-8AC642173D50
P2860
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evaluation of orally active poly
@nl
Evaluation of orally active po ...... f early peripheral neuropathy.
@en
type
label
Evaluation of orally active poly
@nl
Evaluation of orally active po ...... f early peripheral neuropathy.
@en
prefLabel
Evaluation of orally active poly
@nl
Evaluation of orally active po ...... f early peripheral neuropathy.
@en
P2093
P1433
P1476
Evaluation of orally active po ...... f early peripheral neuropathy.
@en
P2093
Charniauskaya T
Obrosova IG
Southan GJ
Stevens MJ
P2888
P304
P356
10.1007/S00125-004-1356-0
P50
P577
2004-04-01T00:00:00Z